SEC 13F Intelligence

Managers / Q4 2022 · view latest →

Rhenman & Partners Asset Management AB

CIK 0001599882 · STRANDVAGEN 5A, STOCKHOLM, 11451 · 4684598880

Reported Value
$958M
Q4 2022
Positions
93
Filings on Record
31
2019–present window
Filed
Feb 13, 2023
original filing

Summary

Rhenman & Partners Asset Management AB reported $958M in U.S.-listed holdings across 93 positions for Q4 2022.

Its largest position, LLY, represents 3.4% of the portfolio.

Compared with Q3 2022, the fund opened 7 new positions and exited 4.

Portfolio Metrics

Turnover
+12.7%
vs prior filed quarter
Top-10 Concentration
+27.3%
share of reported value
Largest Position
+3.4%
Lilly Eli
New / Exited
7 / 4
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $875MQ4 ’18Q1 ’19: $855MQ2 ’19: $908MQ3 ’19: $798MQ4 ’19: $913MQ4 ’19Q1 ’20: $714MQ2 ’20: $926MQ3 ’20: $1.1BQ4 ’20: $1.2BQ4 ’20Q1 ’21: $1.4BQ2 ’21: $1.5BQ3 ’21: $1.4BQ4 ’21: $1.5BQ4 ’21Q1 ’22: $1.0BQ2 ’22: $880MQ3 ’22: $955MQ4 ’22: $958MQ4 ’22Q1 ’23: $911MQ2 ’23: $949MQ3 ’23: $928MQ4 ’23: $1.0BQ4 ’23Q1 ’24: $1.1BQ2 ’24: $1.0BQ3 ’24: $1.2BQ4 ’24: $973MQ4 ’24Q1 ’25: $870MQ2 ’25: $791MQ3 ’25: $904MQ4 ’25: $1.1BQ4 ’25Q1 ’26: $810Mfilingsflow.com

Portfolio Composition

By security type
Common Stock: 93.6%Other: 3.8%ADR: 2.6%
  • Common Stock · 93.6% · $897M
  • Other · 3.8% · $36M
  • ADR · 2.6% · $25M

Quarter-over-Quarter Changes full breakdown →

vs Q3 2022 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
TECHBIO-TECHNE CORPNEW+90.0K90.0K+$7M$7M
OAK STR HEALTH INCNEW+250.0K250.0K+$5M$5M
IQVIQVIA HLDGS INCNEW+20.0K20.0K+$4M$4M
RLAYRELAY THERAPEUTICS INCNEW+200.0K200.0K+$3M$3M
NUVLNUVALENT INCNEW+80.0K80.0K+$2M$2M
MERSANA THERAPEUTICS INCNEW+400.0K400.0K+$2M$2M
IGM BIOSCIENCES INCNEW+50.0K50.0K+$850,500$850,500
SHOCKWAVE MEDICAL INCADDED+27.0K47.0K+$4M$10M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q4 2022

93 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1LLYLILLY ELI & COhistory →COM3.36%$32M88.0K
2CORAMERISOURCEBERGEN CORPhistory →COM2.99%$29M173.0K
3MDTMEDTRONIC PLChistory →SHS2.84%$27M350.0K
4BSXBOSTON SCIENTIFIC CORPhistory →COM2.82%$27M585.0K
5REGNREGENERON PHARMACEUTICALShistory →COM2.79%$27M37.0K
6BMRNBIOMARIN PHARMACEUTICAL INChistory →COM2.74%$26M254.0K
7MRKMERCK & CO. INChistory →COM2.49%$24M215.0K
8GILDGILEAD SCIENCES INChistory →COM2.42%$23M270.0K
9VRTXVERTEX PHARMACEUTICALS INChistory →COM2.41%$23M80.0K
10ELVELEVANCE HEALTH INChistory →COM2.41%$23M45.0K
11THCTENET HEALTHCARE CORPhistory →COM NEW2.40%$23M470.8K
12TMOTHERMO FISHER SCIENTIFIC INChistory →COM2.30%$22M40.0K
13HCAHCA HEALTHCARE INChistory →COM2.25%$22M90.0K
14BDXBECTON DICKINSON & COhistory →COM2.20%$21M83.0K
15ABBVABBVIE INChistory →COM2.19%$21M130.0K
16CICIGNA CORP NEWhistory →COM2.14%$21M62.0K
17JAZZJAZZ PHARMACEUTICALS PLChistory →SHS USD2.13%$20M128.0K
18UNHUNITED HEALTH GROUP INChistory →COM2.10%$20M38.0K
19HUMHUMANA INChistory →COM2.08%$20M39.0K
20PFEPFIZER INChistory →COM1.87%$18M350.0K
21JNJJOHNSON & JOHNSONhistory →COM1.84%$18M100.0K
22ALNYALNYLAM PHARMACEUTICALS INChistory →COM1.81%$17M73.0K
23BNTXBIONTECH SEhistory →SPONSORED ADS1.71%$16M109.0K
24CVSCVS HEALTH CORPhistory →COM1.66%$16M171.0K
25COOPER COS INCCOM NEW1.62%$16M47.0K
26INSPINSPIRE MED SYS INChistory →COM1.60%$15M61.0K
27MCKMCKESSON CORPhistory →COM1.53%$15M39.0K
28AXONICS INCCOM1.50%$14M230.0K
29MIRATI THERAPEUTICS INCCOM1.42%$14M300.0K
30DHRDANAHER CORPORATIONhistory →COM1.38%$13M50.0K
31HRMYHARMONY BIOSCIENCES HLDGS INhistory →COM1.38%$13M240.0K
32ABTABBOTT LABShistory →COM1.34%$13M117.0K
33EWEDWARDS LIFESCIENCES CORPhistory →COM1.12%$11M144.0K
34SILK RD MED INCCOM1.08%$10M195.9K
35APELLIS PHARMACEUTICALS INCCOM1.08%$10M200.0K
36NBIXNEUROCRINE BIOSCIENCES INChistory →COM1.06%$10M85.0K
37CYTKCYTOKINETICS INChistory →COM NEW1.03%$10M216.3K
38SHOCKWAVE MEDICAL INCCOM1.01%$10M47.0K
39OMGBPOUTSET MED INCCOM0.97%$9M360.0K
40IVERIC BIO INCCOM0.96%$9M430.0K
41IMCRIMMUNOCORE HLDGS PLCADS0.89%$9M150.0K
42PODDINSULET CORPCOM0.89%$9M29.0K
43RPRXROYALTY PHARMA PLCSHS CLASS A0.89%$8M215.0K
44PRVAPRIVIA HEALTH GROUP INCCOM0.88%$8M370.0K
45DVAXDYNAVAX TECHNOLOGIES CORPCOM NEW0.87%$8M783.5K
46BIIBBIOGEN INCCOM0.87%$8M30.0K
47REVANCE THERAPEUTICS INCCOM0.84%$8M438.0K
48XNCRXENCOR INCCOM0.80%$8M294.1K
49TECHBIO-TECHNE CORPCOM0.78%$7M90.0K
50IMMUNOGEN INCCOM0.78%$7M1.50M
51NTRANATERA INCCOM0.69%$7M165.0K
52INTRA-CELLULAR THERAPIES INCCOM0.69%$7M125.0K
53KARUNA THERAPEUTICS INCCOM0.62%$6M30.0K
54WSTWEST PHARMACEUTICAL SVSC INCCOM0.61%$6M25.0K
55ESPRESPERION THERAPEUTICS INC NECOM0.58%$6M900.0K
56VEEVVEEVA SYS INCCL A COM0.58%$6M34.5K
57IOVAIOVANCE BIOTHERAPEUTICS INCCOM0.58%$6M864.4K
58NVSTENVISTA HOLDINGS CORPORATIONCOM0.58%$6M163.8K
59EXKEXACT SCIENCES CORPCOM0.57%$5M110.0K
60OAK STR HEALTH INCCOM0.56%$5M250.0K
61SEAGEN INCCOM0.55%$5M41.0K
62OLINK HLDG ABSPONSORED ADS0.51%$5M194.4K
63PHRPHREESIA INCCOM0.51%$5M150.0K
64VRAYQVIEWRAY INCCOM0.47%$4M1.00M
65R1 RCM INCCOM0.43%$4M378.0K
66AGILON HEALTH INCCOM0.43%$4M255.0K
67IQVIQVIA HLDGS INCCOM0.43%$4M20.0K
68ALKSALKERMES PLCSHS0.41%$4M150.0K
69ALHCALIGNMENT HEALTHCARE INCCOM0.40%$4M325.0K
70GKOSGLAUKOS CORPCOM0.39%$4M85.0K
71MEIRAGTX HLDGS PLCCOM0.38%$4M555.0K
72TDOCTELADOC HEALTH INCCOM0.32%$3M130.0K
73RLAYRELAY THERAPEUTICS INCCOM0.31%$3M200.0K
74ARVNARVINAS INCCOM0.30%$3M85.0K
75TXG10X GENOMICS INCCL A COM0.29%$3M75.0K
76PHATPHATHOM PHARMACEUTICALS INCCOM0.28%$3M235.2K
77SGMOQSANGAMO THERAPEUTICS INCCOM0.27%$3M820.0K
78NVCRNOVOCURE LTDORD SHS0.27%$3M35.0K
79NUVLNUVALENT INCCOM0.25%$2M80.0K
80MERSANA THERAPEUTICS INCCOM0.24%$2M400.0K
81ALLOALLOGENE THERAPEUTICS INCCOM0.22%$2M340.0K
82G1 THERAPEUTICS INCCOM0.21%$2M370.0K
83HCATHEALTH CATALYST INCCOM0.20%$2M180.0K
84IONSIONIS PHARMACEUTICALS INCCOM0.20%$2M50.0K
85RIGEL PHARMACEUTICALS INCCOM NEW0.19%$2M1.23M
86NTLAINTELLIA THERAPEUTICS INCCOM0.18%$2M50.0K
87STXSSTEREOTAXIS INCCOM NEW0.17%$2M797.3K
88ISRGINTUITIVE SURGICAL INCCOM NEW0.14%$1M5.0K
89NEKTAR THERAPEUTICSCOM0.13%$1M550.0K
90NKTXNKARTA INCCOM0.12%$1M200.0K
91ESSA PHARMA INCCOM NEW0.10%$945,000375.0K
92IGM BIOSCIENCES INCCOM0.09%$850,50050.0K
93RPIDRAPID MICRO BIOSYSTEMS INCCLASS A COM0.04%$339,000300.0K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$810M86May 14, 202613F-HRchanges · EDGAR ↗
Q4 2025$1.1B94Feb 13, 202613F-HRchanges · EDGAR ↗
Q3 2025$904M92Nov 13, 202513F-HRchanges · EDGAR ↗
Q2 2025$791M90Aug 13, 202513F-HRchanges · EDGAR ↗
Q1 2025$870M94May 14, 202513F-HRchanges · EDGAR ↗
Q4 2024$973M92Feb 13, 202513F-HRchanges · EDGAR ↗
Q3 2024$1.2B95Nov 13, 202413F-HRchanges · EDGAR ↗
Q2 2024$1.0B93Aug 13, 202413F-HRchanges · EDGAR ↗
Q1 2024$1.1B84May 14, 202413F-HRchanges · EDGAR ↗
Q4 2023$1.0B85Feb 13, 202413F-HRchanges · EDGAR ↗
Q3 2023$928M85Nov 13, 2023RESTATEMENTchanges · EDGAR ↗
Q2 2023$949M83Aug 11, 202313F-HRchanges · EDGAR ↗
Q1 2023$911M88May 12, 202313F-HRchanges · EDGAR ↗
Q4 2022$958M93Feb 13, 202313F-HRchanges · EDGAR ↗
Q3 2022$955M90Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$880M86Aug 12, 202213F-HRchanges · EDGAR ↗
Q1 2022$1.0B89May 13, 202213F-HRchanges · EDGAR ↗
Q4 2021$1.5B92Feb 11, 202213F-HRchanges · EDGAR ↗
Q3 2021$1.4B92Nov 12, 202113F-HRchanges · EDGAR ↗
Q2 2021$1.5B94Aug 13, 202113F-HRchanges · EDGAR ↗
Q1 2021$1.4B92May 14, 202113F-HRchanges · EDGAR ↗
Q4 2020$1.2B83Jan 19, 202113F-HRchanges · EDGAR ↗
Q3 2020$1.1B82Oct 13, 202013F-HRchanges · EDGAR ↗
Q2 2020$926M94Jul 16, 202013F-HRchanges · EDGAR ↗
Q1 2020$714M85Apr 16, 202013F-HRchanges · EDGAR ↗
Q4 2019$913M94Jan 17, 202013F-HRchanges · EDGAR ↗
Q3 2019$798M93Oct 16, 201913F-HRchanges · EDGAR ↗
Q2 2019$908M88Jul 22, 201913F-HRchanges · EDGAR ↗
Q1 2019$855M93Apr 11, 201913F-HRchanges · EDGAR ↗
Q4 2018$875M89Feb 5, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.